Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions

P.E. Langton, Graeme Hankey, J.W. Eikelboom

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	524-525
Journal	Medical Journal of Australia
Volume	181
Issue number	10
DOIs	https://doi.org/10.5694/j.1326-5377.2004.tb06433.x
Publication status	Published - 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{b5299487891e45c1820c592c726936fe,

title = "Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions",

author = "P.E. Langton and Graeme Hankey and J.W. Eikelboom",

year = "2004",

doi = "10.5694/j.1326-5377.2004.tb06433.x",

language = "English",

volume = "181",

pages = "524--525",

journal = "Medical Journal of Australia",

issn = "0025-729X",

publisher = "Australasian Medical Publishing Co. Ltd",

number = "10",

}

TY - JOUR

T1 - Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions

AU - Langton, P.E.

AU - Hankey, Graeme

AU - Eikelboom, J.W.

PY - 2004

Y1 - 2004

UR - https://www.scopus.com/pages/publications/9144269923

U2 - 10.5694/j.1326-5377.2004.tb06433.x

DO - 10.5694/j.1326-5377.2004.tb06433.x

M3 - Editorial

SN - 0025-729X

VL - 181

SP - 524

EP - 525

JO - Medical Journal of Australia

JF - Medical Journal of Australia

IS - 10

ER -